Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Taisho’s Nonprescription Anti-Obesity Drug to Hit Pharmacy Shelves on April 8
March 6, 2024
- Mitsubishi, Daiichi Sankyo to Wind Up Diabetes Collab
March 6, 2024
- Kyowa Pharma Joins Medipal-JWP JV, Now Sister Firm to Nichi-Iko
March 6, 2024
- Shionogi, FunPep Enter Option Deal for Pollen Allergy Vaccine
March 6, 2024
- Astellas Kicks Off Japan PIII Studies for Hot Flash Med
March 5, 2024
- EU Regulators Accept Daiichi Sankyo’s TROP2 ADC for Review in Lung, Breast Cancers
March 5, 2024
- Shionogi, Osaka University Set Up Joint Research Lab on Long COVID
March 4, 2024
- Shionogi Healthcare Launches OTC Version of Mucodyne
March 4, 2024
- Taiho Picks Up Rights to China Pharma’s Lung Cancer Drug
March 4, 2024
- Moderna Japan Taps Kazumasa Nagayama as New President
March 4, 2024
- Drugstore Chains Tsuruha and Welcia to Merge, Eye Definite Pact by 2027-End
March 1, 2024
- FoundationOne Approved as CDx for Retevmo in Japan: Chugai
March 1, 2024
- MSD Files Keytruda Plus Chemoradiotherapy for Cervical Cancer in Japan
March 1, 2024
- Otsuka, AN Ventures Hook Up on US$30 Million Investment
February 29, 2024
- Santen Seeks Japan Nod for Eye Drop Targeting Myopia
February 29, 2024
- Pfizer Submits Hemophilia Treatment Marstacimab in Japan
February 29, 2024
- Gilead Files Truvada for HIV Prevention in Japan
February 29, 2024
- Towa to Roll Out New WPP Strategy to Maintain NHI Prices of Key Medicines
February 28, 2024
- Takeda to Outsource Dengue Vaccine Production to India’s Biological E
February 28, 2024
- Mitsubishi Chemical Scraps Regenerative Medicine Unit
February 28, 2024
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…